| Description |
hCAI/II-IN-2 (compound 2b) is a potent dual hCA I/II inhibitor with Ki values of 40.97, 15.15 and 61.88 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-2 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity[1].
|
| Related Catalog |
|
| In Vitro |
hCAI/II-IN-2 (compound 2b) (5-200 μM, 48 hours; HEK293T cells) has no obvious toxicity at HEK293T cells[1]. Cell Cytotoxicity Assay[1] Cell Line: Embryonic kidney (HEK293T) cells Concentration: 5, 25, 50, 100 and 200 μM Incubation Time: 48 hours Result: Had no apparent cytotoxicity.
|
| In Vivo |
Animal Model: Male BLAB/c mice[1] Dosage: 400 mg/kg Administration: Oral administration; 14 days. Result: Prolonged the survival time of mice by 21.7% compared with the blank control group.
|
| References |
[1]. Yang C, et al. N-Quinary heterocycle-4-sulphamoylbenzamides exert anti-hypoxic effects as dual inhibitors of carbonic anhydrases I/II. Bioorg Chem. 2020 Jul;100:103931.
|
